Madrigal Pharmaceuticals, Inc.
MDGL· Nasdaq
Released Nov 9, 2017, before the open
10-Q filed Nov 9, 2017, 40 days after period end · 0001104659-17-067118
| Metric | Q3 2017 | Q3 2016 | Q3 2015 | Q3 2014 |
|---|---|---|---|---|
| Net Income | -$8.36M | -$14.05M | — | — |
| EPS Diluted | -$0.68 | -$1.59 | -$10.46 | -$0.19 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Madrigal Pharmaceuticals, Inc. · CIK 1157601 · Engraved from SEC EDGAR